Latest Articles
Can immuno-oncology revolutionize endometrial cancer treatment in Korea? - KBR
Can immuno-oncology revolutionize endometrial cancer treatment in Korea? KBR
Published: March 4, 2025, 7:13 a.m.
A Rare Case of Endometrial Adenosarcoma and Its Management: A Case Report and Literature Review - Cureus
A Rare Case of Endometrial Adenosarcoma and Its Management: A Case Report and Literature Review Cureus
Published: March 3, 2025, 5:57 p.m.
Doctor develops non-invasive test for endometrial cancer - KJZZ
Doctor develops non-invasive test for endometrial cancer KJZZ
Published: March 3, 2025, noon
Arizona doctor develops non-invasive test for endometrial cancer - KJZZ
Arizona doctor develops non-invasive test for endometrial cancer KJZZ
Published: March 3, 2025, noon
The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer - Nature.com
The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer Nature.com
Published: March 3, 2025, 11:33 a.m.
of endometrial receptivity analysis - ResearchGate
of endometrial receptivity analysis ResearchGate
Published: March 2, 2025, 3:53 a.m.
The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation - Nature.com
The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation Nature.com
Published: March 1, 2025, 2:30 p.m.
Characteristics of Patients Undergoing Laparoscopic Hysterectomy for Atypical Endometrial Hyperplasia - Cureus
Characteristics of Patients Undergoing Laparoscopic Hysterectomy for Atypical Endometrial Hyperplasia Cureus
Published: March 1, 2025, 5:24 a.m.
Tumor Volume Index as a Predictor of Pelvic Lymph Node Metastasis in Low-Risk Endometrial Cancer - Cureus
Tumor Volume Index as a Predictor of Pelvic Lymph Node Metastasis in Low-Risk Endometrial Cancer Cureus
Published: Feb. 28, 2025, 6:36 p.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central
Published: Feb. 28, 2025, 10:47 a.m.
Link copied to clipboard!